Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transmedics Group Inc (TMDX)

Transmedics Group Inc (TMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,392,041
  • Shares Outstanding, K 34,174
  • Annual Sales, $ 441,540 K
  • Annual Income, $ 35,460 K
  • EBIT $ 96 M
  • EBITDA $ 116 M
  • 60-Month Beta 2.06
  • Price/Sales 8.88
  • Price/Cash Flow 81.01
  • Price/Book 12.82

Options Overview Details

View History
  • Implied Volatility 83.93% (-2.20%)
  • Historical Volatility 44.35%
  • IV Percentile 73%
  • IV Rank 49.52%
  • IV High 124.49% on 02/27/25
  • IV Low 44.14% on 06/10/25
  • Expected Move (DTE 7) 6.58 (5.07%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 575
  • Volume Avg (30-Day) 888
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 20,189
  • Open Int (30-Day) 19,157
  • Expected Range 123.26 to 136.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.41
  • Number of Estimates 7
  • High Estimate 0.55
  • Low Estimate 0.28
  • Prior Year 0.19
  • Growth Rate Est. (year over year) +115.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.00 +2.24%
on 02/05/26
149.22 -12.99%
on 01/16/26
-12.87 (-9.02%)
since 01/13/26
3-Month
111.04 +16.93%
on 11/14/25
156.00 -16.77%
on 12/02/25
+14.29 (+12.37%)
since 11/13/25
52-Week
62.07 +109.17%
on 03/06/25
156.00 -16.77%
on 12/02/25
+58.62 (+82.31%)
since 02/13/25

Most Recent Stories

More News
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

ANDOVER, Mass. , Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial

ANDOVER, Mass. , Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts

ANDOVER, Mass. , Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing...

TMDX : 129.84 (+1.03%)
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ANDOVER, Mass. , Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Dec. 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference

ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics: Q3 Earnings Snapshot

TransMedics: Q3 Earnings Snapshot

TMDX : 129.84 (+1.03%)
TransMedics Reports Third Quarter 2025 Financial Results

ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025

ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 129.84 (+1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation....

See More

Key Turning Points

3rd Resistance Point 136.93
2nd Resistance Point 134.57
1st Resistance Point 132.21
Last Price 129.84
1st Support Level 127.49
2nd Support Level 125.13
3rd Support Level 122.77

See More

52-Week High 156.00
Last Price 129.84
Fibonacci 61.8% 120.12
Fibonacci 50% 109.04
Fibonacci 38.2% 97.95
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar